SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E. Campo, S. Rule, Mantle cell lymphoma: evolving management strategies, Blood, 2015, 125, 1, 48

    CrossRef

  2. 2
    S Robinson, P Dreger, D Caballero, P Corradini, C Geisler, M Ghielmini, S Le Gouill, E Kimby, S Rule, U Vitolo, M Dreyling, O Hermine, The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma, Leukemia, 2015, 29, 2, 464

    CrossRef

  3. 3
    R. Syha, L. Grünwald, T. Horger, D. Spira, D. Ketelsen, W. Vogel, C. D. Claussen, M. Horger, Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography, European Radiology, 2014, 24, 3, 770

    CrossRef

  4. 4
    Erik Magnusson, Qing Cao, Michael A. Linden, Jerry Frolich, Vidhu Anand, Linda J. Burns, Veronika Bachanova, Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: Predictive Value of Pretransplant Positron Emission Tomography/Computed Tomography and Bone Marrow Evaluations for Outcomes, Clinical Lymphoma Myeloma and Leukemia, 2014, 14, 2, 114

    CrossRef

  5. 5
    M Dreyling, S Ferrero, O Hermine, How to manage mantle cell lymphoma, Leukemia, 2014, 28, 11, 2117

    CrossRef

  6. 6
    Meirav Kedmi, Irit Avivi, Elena Ribakovsky, Noam Benyamini, Tima Davidson, Elinor Goshen, Tamar Tadmor, Arnon Nagler, Abraham Avigdor, Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma?, Leukemia & Lymphoma, 2014, 55, 11, 2484

    CrossRef

  7. 7
    A. Kolstad, A. Laurell, M. Jerkeman, K. Gronbaek, E. Elonen, R. Raty, L. B. Pedersen, A. Loft, T. V. Bogsrud, E. Kimby, P. B. Hansen, U.-M. Fagerli, H. Nilsson-Ehle, G. F. Lauritzsen, A. K. Lehmann, C. Sundstrom, M.-L. Karjalainen-Lindsberg, E. Ralfkiaer, M. Ehinger, J. Delabie, H. Bentzen, J. Schildt, K. Kostova-Aherdan, H. Frederiksen, P. d. N. Brown, C. H. Geisler, Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma, Blood, 2014, 123, 19, 2953

    CrossRef

  8. 8
    J B Cohen, N C Hall, A S Ruppert, J A Jones, P Porcu, R Baiocchi, B A Christian, S Penza, D M Benson, J Flynn, L A Andritsos, S M Devine, K A Blum, Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma, Bone Marrow Transplantation, 2013, 48, 9, 1212

    CrossRef

  9. 9
    C. Bodet-Milin, T. Eugène, T. Gastinne, C. Bailly, S. Le Gouill, B. Dupas, F. Kraeber-Bodéré, La place de la TEP au FDG dans l’évaluation des lymphomes en 2012, Journal de Radiologie Diagnostique et Interventionnelle, 2013, 94, 2, 164

    CrossRef

  10. 10
    Andre Goy, Mantle cell lymphoma: continuously improving the odds!, Expert Opinion on Orphan Drugs, 2013, 1, 12, 1001

    CrossRef

  11. 11
    Ukihide Tateishi, PET/CT in malignant lymphoma: basic information, clinical application, and proposal, International Journal of Hematology, 2013, 98, 4, 398

    CrossRef

  12. 12
    Yuyuan Zhu, Jianda Lu, Xin Wei, Shaoli Song, Gang Huang, The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis, BioMed Research International, 2013, 2013, 1

    CrossRef

  13. 13
    C. Bodet-Milin, T. Eugène, T. Gastinne, C. Bailly, S. Le Gouill, B. Dupas, F. Kraeber-Bodéré, The role of FDG-PET scanning in assessing lymphoma in 2012, Diagnostic and Interventional Imaging, 2013, 94, 2, 158

    CrossRef